Diamond Equity Equities Analysts Decrease Earnings Estimates for YS Biopharma Co., Ltd. (NASDAQ:YS)

YS Biopharma Co., Ltd. (NASDAQ:YS) – Equities research analysts at Diamond Equity cut their FY2024 earnings per share estimates for shares of YS Biopharma in a research note issued on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($0.45) for the year, down from their prior forecast of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.24) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.

YS Biopharma Stock Performance

YS stock opened at $0.80 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. YS Biopharma has a one year low of $0.35 and a one year high of $1.97. The firm’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.57.

YS Biopharma (NASDAQ:YS) last issued its earnings results on Monday, January 22nd. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $13.64 million during the quarter.

Institutional Trading of YS Biopharma

A hedge fund recently bought a new stake in YS Biopharma stock. Superstring Capital Management LP acquired a new stake in YS Biopharma Co., Ltd. (NASDAQ:YS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned approximately 0.33% of YS Biopharma at the end of the most recent reporting period. 52.64% of the stock is currently owned by hedge funds and other institutional investors.

About YS Biopharma

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.